Cite
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo.
MLA
Yin, Fanxiang, et al. “Novel Dual Inhibitor for Targeting PIM1 and FGFR1 Kinases Inhibits Colorectal Cancer Growth in Vitro and Patient-Derived Xenografts in Vivo.” Acta Pharmaceutica Sinica B, vol. 12, no. 11, Nov. 2022, pp. 4122–37. EBSCOhost, https://doi.org/10.1016/j.apsb.2022.07.005.
APA
Yin, F., Zhao, R., Gorja, D. R., Fu, X., Lu, N., Huang, H., Xu, B., Chen, H., Shim, J.-H., Liu, K., Li, Z., Laster, K. V., Dong, Z., & Lee, M.-H. (2022). Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo. Acta Pharmaceutica Sinica B, 12(11), 4122–4137. https://doi.org/10.1016/j.apsb.2022.07.005
Chicago
Yin, Fanxiang, Ran Zhao, Dhilli Rao Gorja, Xiaorong Fu, Ning Lu, Hai Huang, Beibei Xu, et al. 2022. “Novel Dual Inhibitor for Targeting PIM1 and FGFR1 Kinases Inhibits Colorectal Cancer Growth in Vitro and Patient-Derived Xenografts in Vivo.” Acta Pharmaceutica Sinica B 12 (11): 4122–37. doi:10.1016/j.apsb.2022.07.005.